2ND INTERNATIONAL RESEARCH MEETING
3rd JUNE 2010- HÔTEL DE MARIGNY PARIS

2009 CNS MEETING FOLLOW-UP: WHAT HAS CHANGED?
FINAL PROGRAM

16H00 PM: Official opening by the Minister Madame Roselyne Bachelot

16H30 PM: Introduction by Pharmaceutical Industry representatives: Dominique Amory and Christian Lajoux

16H45 PM: The key success factors for a successful public private partnership in life sciences: Video of Elias Zerhouni

16H50 PM: ROUNDTABLE DISCUSSION: WHAT HAS CHANGED SINCE LAST YEAR?

- Key data and information : Pr Alexis Brice
- Selected Public-private partnerships Case studies:
  
  – Eli Lilly & MIRCEN
    - Eli Lilly : Michael Hutton Chief Scientific Officer
    - Neurodegenerative Platform
  - Mircen (Molecular Imaging Research Center - site du CEA):
    - Dr Philippe Hantraye
    - Dr Nicole Déglon
  
  – AstraZeneca & NEUROSPIN
    - AstraZeneca (R&D Global Neuroscience):
      - Mattias Lindberg, Senior Responsible Scientist,
      - Patrick Raboission, Director, Analgesia Disease.
    - Neurospin:
      - Dr Jean-René Deverre, Neurospin plateform director,
      - Dr Denis LeBihan, General Director
Roche & ICM & CLINATEC
- General Introduction: Sophie Kornowski-Bonnet, General Manager Roche France: Roche involvement and participation in CNS
- Roche - Clinatec
  - Roche Jean-Luc Moreau, Scientific Expert - Extramural Neuroscience & Operations Manager
  - Clinatec: Pr François Berger, Directeur de recherche Inserm, Nanomédecine et cerveau, University of Grenoble
- Roche – ICM/ IM2A
  - Thomas Blaettler, Clinical Science Leader Neuroscience
  - Pr Bruno Dubois, CHU Pitié Salpêtrière, IM2A (Institut de la mémoire et de la maladie d’Alzheimer)

- P. Amouyel - Public-private partnerships in the context of the foundation for scientific cooperation “Alzheimer’s disease and related diseases”

- Quelques exemples et commentaires complémentaires de la part d'autres industriels
  - Sanofi aventis: Marc Cluzel Executive VP Head of R&D “Partenariat entre Sanofi Aventis et l’Alliance Avisean”
  - Ipsen: Dr. Claude Bertrand Executive Vice-President, Chief Scientific Officer
  - Janssen: Dr. Luc Van Hijfte, Sr Director, Head Medicinal Chemistry European Discovery Capabilities A division of Janssen-Pharmaceuticals
  - Pfizer: Olivier Drap, Associate Director, R&D Business Development à Sandwich (UK)
    « Place of France in Public-private partnerships” at the European level »

- Importance of education and training for efficient and productive PPP
- Prof Jean-Marie Goehrs

18H15 PM: Conclusion by Arnold Munich and André Syrota (Chairman of Aviesan)